CJC-1295 No DAC and Ipamorelin: Research Strength Considerations

For a wholesale buyer, "strength" on these two compounds collapses three separate specifications into one number. There is nominal mass per vial (both are commonly catalogued at 10mg), chromatographic purity (what percentage of that mass is actually the target sequence), and net peptide content (what remains once counterions and residual moisture are accounted for). A 10mg vial backed by a batch-specific certificate of analysis showing 99%+ HPLC purity and a 10mg vial with no published lab data are not equivalent products, and no label will tell you which one you are holding. Before you evaluate anything else about these compounds, evaluate whether the supplier will show you per-lot analytics you can read yourself.

The three numbers behind a single label figure

Nominal fill mass is a manufacturing target, not a measurement of activity. It tells you how much lyophilized material the vial was filled with, and a serious manufacturer can state the fill tolerance they work to. That is the first question, and it is the least interesting of the three.

Chromatographic purity is where the real variance lives. High-performance liquid chromatography separates the contents of a sample and reports what proportion of the detected material corresponds to the intended sequence. The remainder is made up of truncated sequences, deletion sequences, oxidation products, and synthesis byproducts. For research work, this matters because impurities are variables — an uncharacterized impurity profile is an uncontrolled input into whatever assay or model the material is used in.

Net peptide content is the number most buyers never ask about. Synthetic peptides are typically isolated as salts, so acetate or trifluoroacetate counterions and residual water contribute to gross mass. Two vials can both be accurately described as 10mg at high purity and still differ in the actual mass of peptide present. If a manufacturer reports net peptide content, that is a sign of a mature analytical program, not a marketing flourish.

One more distinction worth holding onto: purity is not identity. A chromatogram can show a single clean peak of material that is not the sequence you ordered. Identity confirmation — generally by mass spectrometry — is a separate test, and it belongs on the same certificate.

Why the "no DAC" designation changes the specification conversation

DAC stands for Drug Affinity Complex, a linker chemistry that allows the molecule to bind circulating albumin and remain in circulation considerably longer. The version without that modification is a growth hormone releasing hormone analog based on the GRF (1-29) fragment, and it is widely catalogued and discussed in the literature as modified GRF (1-29) as well as CJC-1295 no DAC. Research in this area suggests the two variants produce meaningfully different pharmacokinetic profiles, which is exactly why the designation cannot be treated as a naming preference.

For a buyer, this creates a concrete sourcing risk. "CJC-1295" used alone is ambiguous, and an ambiguous product page is not resolved by asking a sales rep. It is resolved by reading the certificate of analysis and confirming which sequence the mass spectrometry data describes. If a supplier cannot produce lot-level identity data that distinguishes the two, you are buying on trust rather than on documentation — and if a customer later asks you which variant they received, you will have nothing to point to.

The same care applies to the second compound. Ipamorelin is a short synthetic pentapeptide studied as a selective growth hormone secretagogue receptor agonist. Its small size makes it comparatively straightforward to synthesize cleanly, but small size also means impurities can be structurally close to the target, which puts more weight on the resolution of the analytical method rather than just the headline purity figure.

Label attributes side by side

The two compounds get shelved together often enough that buyers assume their specifications are interchangeable. They are not.

Use the table as a checklist against any supplier's product page. If a page cannot answer the middle three rows, the product is underspecified regardless of what the price looks like.

Keeping the research framing intact

Everything above is a materials-science conversation. These compounds are not FDA-approved drugs, they are not described here for human consumption, and nothing in this article constitutes dosing, administration, or protocol guidance. Where the literature is relevant, it is relevant to what the molecule is and how consistently it can be manufactured — not to outcomes.

That framing has practical consequences for how you stock and describe inventory. Research-use-only material should be catalogued, labeled, and marketed as research-use-only downstream of you as well, and the language your own storefront uses is part of your compliance posture. If a research plan involves animal models, veterinary and institutional oversight sits on top of everything discussed here — talk to your veterinarian and your institutional animal care committee before any in vivo design is finalized.

The regulatory questions that follow are genuinely unsettled from where you are sitting, and they vary by jurisdiction and by business model. Rather than reading a confident answer anywhere online, treat these as questions to bring to counsel: How does your state board characterize research compound resale for a business like yours? What license or registration, if any, attaches to your specific model? What labeling and record-keeping obligations follow from that characterization? What does your professional liability carrier require? This article is informational and is not legal advice — verify specifics with your state board and your attorney before you build a catalog around any answer.

What to verify before committing to any supplier

The verification list is short, and most suppliers fail it in the same predictable places.

Batch-specific COAs you can read without asking. A certificate tied to the exact lot you receive is the only meaningful document. A generic "typical analysis" sheet describes an idealized batch, not yours. Some suppliers treat lab results as a gated asset — available on request, available after purchase, or available for an additional charge. Treat paid or gated COAs as a pricing signal: you are being charged for the evidence that the product is what the label says.

Named analytical methods. "Lab tested" is not a method. "Third-party verified" without a report is not verification. You want HPLC purity with the method stated, identity confirmation, and results attributable to a named lot.

Testing beyond purity. Purity alone does not cover sterility, endotoxin, residual solvents, or heavy metals. A multi-panel batch testing program addresses a broader set of contamination questions than a single chromatogram can.

Lot-to-lot consistency. If you are stocking a compound repeatedly, the relevant question is whether lot three looks like lot one. Ask whether historical COAs remain accessible so you can compare across lots rather than judging a single snapshot.

Fulfillment and handling. Ask where the material ships from, what the realistic turnaround is, and how lyophilized product is handled and protected in transit. Domestic fulfillment shortens the chain and shortens the list of things that can go wrong in customs.

How wholesale pricing and minimums actually work

Wholesale pricing in this category is almost always volume-tiered: per-unit cost falls as committed quantity rises, sometimes per SKU and sometimes across a blended order. Minimum order quantities exist because fill, labeling, and batch release carry fixed costs that do not scale down. Beyond that, specifics vary widely by supplier, by compound, and by how established the account is — so be skeptical of any article quoting you a margin range or an industry-standard minimum. Those numbers are not published, and anyone inventing them for you is guessing.

What you can evaluate is structure. Is the tier schedule visible before you apply, or does it arrive only after a sales call? Are COAs included in the price or billed separately? Is there a documented process for lot traceability if you need to answer a customer question six months from now? Opaque pricing and gated documentation are not neutral choices — they shift risk and information asymmetry onto you, and they tend to travel together.

What Real Peptides does differently

Real Peptides publishes 99%+ HPLC purity as the standard for catalog compounds, runs seven-panel batch testing, and makes certificates of analysis publicly verifiable — meaning a prospective partner can read the lab results before applying, rather than requesting them, paying for them, or taking a claim on faith. Both compounds discussed here are catalogued as research-use-only lyophilized material, including CJC-1295 No DAC 10mg with the variant stated explicitly in the product name, and Ipamorelin 10mg.

Fulfillment runs from within the US on a 5–7 day window, which keeps the handling chain short for lyophilized product. Wholesale access runs through a three-step application to the Wholesale Partner Program: submit the application with your business details, complete verification, and receive tiered wholesale pricing once the account is approved. Pricing tiers and documentation are part of the account, not a reward for surviving a sales sequence.

Taking the next step

If you are building or expanding a research compound catalog, the adjacent categories are worth reviewing alongside these two — the growth factor and tissue signaling research collection covers related signaling compounds, performance and recovery research and mitochondrial and metabolic pathway research cover neighboring areas of study, and compounds such as Tesamorelin 10mg, BPC-157 10mg, and TB-500 10mg are documented to the same analytical standard.

For a business that can verify its credentials and wants pricing tiers with lab documentation attached rather than withheld, the Wholesale Partner Program application is the path — read a published certificate of analysis first, confirm it answers the questions in this article, and apply from there.